Stem Cell Clinic

Stem Cell Therapy Treats Pets

By Stem Cell Treatment

Green Bay -

You hear about people getting stem cell therapy for various ailments. Now it's even available for your pet.

A Northeast Wisconsin veterinary center is the first in the state to offer it. It's not cheap, but we found pet owners feel the results outweigh the cost.

Eleven-year-old DeNiro is about to do something he couldn't do when he was ten. Jump.

Owner Keith Noskowiak couldn't be happier. "That's awesome seeing him be able to do that again."

DeNiro suffered from severe arthritis in his back.

A German shepherd named Shadow had hip dysplasia. She could barely walk, let alone jump as she can today, catching balls in flight.

"She would whimper all night long because she was starting to hurt. It was starting to get more severe," owner Luther Kortbein says.

These two German shepherds were the first dogs to receive stem cell therapy in Wisconsin.

Doctor Maura Mansfield from the Packerland Veterinary Center performed the surgeries in June.

Go here to see the original:
Stem Cell Therapy Treats Pets

New stem cell treatment for dogs

By Stem Cell Treatment

GREEN BAY - Statistics show Americans spend almost $51 billion on their pets every year.

A new stem cell treatment for dogs is providing relief for pets and their owners, and now it's being done here in the Green Bay area.

It's designed to treat problems like hip dysplasia and arthritis.

The procedure can cost thousands of dollars, but pet owners believe it is money well-spent.

"Come on buddy," said Keith Moskowiak, De Niro's owner.

Ten-year-old German Shepherd De Niro is at the veterinarian's office for a routine check up.

Owner Keith Moskowiak says De Niro couldn't have done it just two months ago.

"He wasn't able to get around, you could tell he was in a lot of pain," said Moskowiak.

Five-year-old Shadow has hip dysplasia.

"She was slowing herself down, she truly was. She was reserving herself. She'd run a little bit, then she'd sit," said Luther Kortbein, Shadow's owner.

Follow this link:
New stem cell treatment for dogs

University of Maryland study: Neonatal heart stem cells may help mend kids' broken hearts

By Stem Cell Medical Center

Public release date: 10-Sep-2012 [ | E-mail | Share ]

Contact: Bill Seiler bseiler@umm.edu 410-328-8919 University of Maryland Medical Center

Baltimore, MD September 10, 2012 Researchers at the University of Maryland School of Medicine, who are exploring novel ways to treat serious heart problems in children, have conducted the first direct comparison of the regenerative abilities of neonatal and adult-derived human cardiac stem cells. Among their findings: cardiac stem cells (CSCs) from newborns have a three-fold ability to restore heart function to nearly normal levels compared with adult CSCs. Further, in animal models of heart attack, hearts treated with neonatal stem cells pumped stronger than those given adult cells. The study is published in the September 11, 2012, issue of Circulation.

"The surprising finding is that the cells from neonates are extremely regenerative and perform better than adult stem cells," says the study's senor author, Sunjay Kaushal, M.D., Ph.D., associate professor of surgery at the University of Maryland School of Medicine and director, pediatric cardiac surgery at the University of Maryland Medical Center. "We are extremely excited and hopeful that this new cell-based therapy can play an important role in the treatment of children with congenital heart disease, many of whom don't have other options."

Dr. Kaushal envisions cellular therapy as either a stand-alone therapy for children with heart failure or an adjunct to medical and surgical treatments. While surgery can provide structural relief for some patients with congenital heart disease and medicine can boost heart function up to two percent, he says cellular therapy may improve heart function even more dramatically. "We're looking at this type of therapy to improve heart function in children by 10, 12, or 15 percent. This will be a quantum leap in heart function improvement."

Heart failure in children, as in adults, has been on the rise in the past decade and the prognosis for patients hospitalized with heart failure remains poor. In contrast to adults, Dr. Kaushal says heart failure in children is typically the result of a constellation of problems: reduced cardiac blood flow; weakening and enlargement of the heart; and various congenital malformations. Recent research has shown that several types of cardiac stem cells can help the heart repair itself, essentially reversing the theory that a broken heart cannot be mended.

Stem cells are unspecialized cells that can become tissue- or organ-specific cells with a particular function. In a process called differentiation, cardiac stem cells may develop into rhythmically contracting muscle cells, smooth muscle cells or endothelial cells. Stem cells in the heart may also secrete growth factors conducive to forming heart muscle and keeping the muscle from dying.

To conduct the study, researchers obtained a small amount of heart tissue during normal cardiac surgery from 43 neonates and 13 adults. The cells were expanded in a growth medium yielding millions of cells. The researchers developed a consistent way to isolate and grow neonatal stem cells from as little as 20 milligrams of heart tissue. Adult and neonate stem cell activity was observed both in the laboratory and in animal models. In addition, the animal models were compared to controls that were not given the stem cells.

Dr. Kaushal says it is not clear why the neonatal stem cells performed so well. One explanation hinges on sheer numbers: there are many more stem cells in a baby's heart than in the adult heart. Another explanation: neonate-derived cells release more growth factors that trigger blood vessel development and/or preservation than adult cells.

"This research provides an important link in our quest to understand how stem cells function and how they can best be applied to cure disease and correct medical deficiencies," says E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs, University of Maryland; the John Z. and Akiko K. Bowers Distinguished Professor; and dean, University of Maryland School of Medicine. "Sometimes simple science is the best science. In this case, a basic, comparative study has revealed in stark terms the powerful regenerative qualities of neonatal cardiac stem cells, heretofore unknown."

See the rest here:
University of Maryland study: Neonatal heart stem cells may help mend kids' broken hearts

State stem cell research funding agency awards $37.3 million to aid UC Irvine efforts

By Stem Cell Clinic

Public release date: 6-Sep-2012 [ | E-mail | Share ]

Contact: Tom Vasich tmvasich@uci.edu 949-824-6455 University of California - Irvine

Irvine, Calif., Sept. 6, 2012 Efforts to begin human clinical trials using stem cells to treat Alzheimer's disease and retinitis pigmentosa received a $37.3 million boost from the California Institute for Regenerative Medicine during its most recent round of funding on Sept. 5.

UC Irvine scientists will be part of two research teams garnering CIRM Disease Team Therapy Development Awards, which are designed to accelerate collaborative translational research leading to human clinical trials. In one, Dr. Henry Klassen, an associate professor of ophthalmology in UC Irvine's Sue & Bill Gross Stem Cell Research Center, and his collaborators at UC Santa Barbara and Cedars-Sinai Medical Center, received $17.3 million to cultivate therapeutically potent retinal progenitor stem cells to treat the blinding effects of retinitis pigmentosa.

In the other, StemCells, Inc. in Newark, Calif., received $20 million and will collaborate with Frank LaFerla and Mathew Blurton-Jones neurobiologists with the stem cell research center and the Institute for Memory Impairments and Neurological Disorders (UCI MIND) to advance research using the company's proprietary purified human neural stem cells to improve memory in people with Alzheimer's disease.

"CIRM's support for UC Irvine's efforts to advance stem cell-based treatments for a variety of diseases is extremely gratifying," said Peter Donovan, director of the Sue & Bill Gross Stem Cell Research Center. "Henry's work on retinitis pigmentosa and Frank and Mathew's on Alzheimer's disease hold great promise, and we are delighted that they have the support to see their work move toward the clinic."

Klassen's objective is to introduce stem cells that rescue and reactivate damaged and dying photoreceptor rods and cones, thus reversing the course of RP even at relatively advanced stages. The current CIRM funding will allow Klassen and his collaborators to grow these cells under conditions ensuring that pharmaceutical standards are met. The resulting cells will be tested in animals for safety and to make certain that they are therapeutically potent. Then the team will seek FDA approval for the use of these cells in early clinical trials, in which a small number of patients with severe RP will be injected with cells in their worse-seeing eye and followed clinically for a specified period of time to determine the safety and effectiveness of the treatment.

"We believe it's possible to rejuvenate a clinically significant number of cones in the degenerating retina," said Klassen, whose work also has received long-standing support from the Discovery Eye Foundation. "Our methods have been validated, and I'm optimistic that stem cell-based treatments can help restore fading vision in people with eye diseases."

The CIRM award will further LaFerla and Blurton-Jones's efforts with StemCells, Inc. to understand how human neural stem cells can treat Alzheimer's disease, the leading cause of dementia in the U.S. Earlier this year, the researchers reported findings showing that neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease, possibly by providing growth factors that protect neurons from degeneration. With these studies establishing proof of concept, the team intends to conduct further animal studies necessary to seek FDA approval to start testing this therapeutic approach in human patients.

"Our goal is to research ways to make memories last a lifetime, and we're excited to investigate the potential efficacy of stem cells for Alzheimer's disease," said LaFerla, the UCI MIND director and Chancellor's Professor and chair of neurobiology & behavior.

Link:
State stem cell research funding agency awards $37.3 million to aid UC Irvine efforts

Could this stem cell cure for wrinkles end the endless hunt for the perfect skin cream?

By Stem Cell Clinic

British firm is trialling new method by injecting patient's own stem cells to restore skin's youthful elasticity

By Tamara Cohen

PUBLISHED: 10:40 EST, 9 September 2012 | UPDATED: 02:12 EST, 10 September 2012

Scientists will begin clinical trials in 12 months, using stem cells harvested from a blood sample from the patients

Scientists are working on a new weapon in the war against wrinkles.

There are not many things women have not tried in the quest for a youthful complexion from lotions and potions to Botox and cosmetic surgery.

But a British firm is trialling a new method which involves injecting the patients own stem cells to restore skins youthful elasticity.

Researchers believe they will spur the growth of new skin cells, called fibroblasts, which make the elastic ingredient collagen which is produced in large quantities when we are young, but declines as we age.

The company Pharmacells, based in Glasgow, plan to begin clinical trials in 12 months, using stem cells harvested from a blood sample from the patients.

They believe the procedure could be commercially available in just three years, potentially revolutionising the market for anti-ageing treatments.

Continue reading here:
Could this stem cell cure for wrinkles end the endless hunt for the perfect skin cream?

Researchers Reveal a Chemotherapy-Resistant Cancer Stem Cell as the "Achilles' Heel" of Cancer

By Uncategorized

Newswise Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell.

Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer stem cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die.

Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers of embryonic development. In addition, these cells displayed cancer stem cell functions, including the capacity to initiate tumor cell growth. Next, the team evaluated human tissue samples of prostate cancer and found that patients with more aggressive or metastatic tumors had more of these cancer stem cells.

This is the first time these so-called cancer stem cells of prostate have been identified as the basis for drug resistance and tumor progression, indicating that they are cancers Achilles Heel, said Dr. Cordon-Cardo. These findings are the culmination of more than six years of innovative research, which has led to the successful unveiling of cancer characteristics that are critical to understanding how the disease works and progresses.

The study also defines a new therapeutic strategy for patients with prostate cancer, consisting of a combination of standard chemotherapy and two pharmacological agents that inhibit key signaling pathways associated with embryonic development and cell differentiation. Results showed that chemotherapy eliminated differentiated tumor cells, whereas the signaling pathway inhibitors selectively depleted the cancer stem cell population. Some of these inhibitors are already in clinical trials, and some are FDA-approved.

By targeting these newly identified cancer stem cells, we are attacking the foundation of tumor growth, rather than treating the symptoms of it, said Dr. Domingo-Domenech. The novel discovery of this cell population could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies.

Ongoing studies suggest that this new cell type exist in other tumor types such as breast cancer, colon cancer, bladder cancer and lung cancer. Dr. Cordon-Cardos team is studying these disease areas to determine the presence and impact of these cancer cells.

About The Mount Sinai Medical Center The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by US News and World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nations oldest, largest and most-respected voluntary hospitals. In 2011, US News and World Report ranked The Mount Sinai Hospital 16th on its elite Honor Roll of the nations top hospitals based on reputation, safety, and other patient-care factors. Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and US News and World Report and whose hospital is on the US News and World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place. For more information, visit http://www.mountsinai.org/.

Find Mount Sinai on: Facebook: http://www.facebook.com/mountsinainyc Twitter: @mountsinainyc YouTube: http://www.youtube.com/mountsinainy

Read more here:
Researchers Reveal a Chemotherapy-Resistant Cancer Stem Cell as the "Achilles' Heel" of Cancer

Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel'

By Uncategorized

Public release date: 10-Sep-2012 [ | E-mail | Share ]

Contact: Mount Sinai Press Office newsmedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine

Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell.

Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer "stem" cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die.

Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers of embryonic development. In addition, these cells displayed cancer stem cell functions, including the capacity to initiate tumor cell growth. Next, the team evaluated human tissue samples of prostate cancer and found that patients with more aggressive or metastatic tumors had more of these cancer "stem" cells.

"This is the first time these so-called cancer stem cells of prostate have been identified as the basis for drug resistance and tumor progression, indicating that they are cancer's 'Achilles Heel,'" said Dr. Cordon-Cardo. "These findings are the culmination of more than six years of innovative research, which has led to the successful unveiling of cancer characteristics that are critical to understanding how the disease works and progresses."

The study also defines a new therapeutic strategy for patients with prostate cancer, consisting of a combination of standard chemotherapy and two pharmacological agents that inhibit key signaling pathways associated with embryonic development and cell differentiation. Results showed that chemotherapy eliminated differentiated tumor cells, whereas the signaling pathway inhibitors selectively depleted the cancer stem cell population. Some of these inhibitors are already in clinical trials, and some are FDA-approved.

"By targeting these newly identified cancer 'stem' cells, we are attacking the foundation of tumor growth, rather than treating the symptoms of it," said Dr. Domingo-Domenech. "The novel discovery of this cell population could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies."

Ongoing studies suggest that this new cell type exist in other tumor types such as breast cancer, colon cancer, bladder cancer and lung cancer. Dr. Cordon-Cardo's team is studying these disease areas to determine the presence and impact of these cancer cells.

###

Continued here:
Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel'

Chemotherapy-resistant cancer stem cell could be 'Achilles' heel' of cancer

By Stem Cell Treatment

ScienceDaily (Sep. 10, 2012) Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell.

Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer "stem" cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die.

Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers of embryonic development. In addition, these cells displayed cancer stem cell functions, including the capacity to initiate tumor cell growth. Next, the team evaluated human tissue samples of prostate cancer and found that patients with more aggressive or metastatic tumors had more of these cancer "stem" cells.

"This is the first time these so-called cancer stem cells of prostate have been identified as the basis for drug resistance and tumor progression, indicating that they are cancer's 'Achilles Heel,'" said Dr. Cordon-Cardo. "These findings are the culmination of more than six years of innovative research, which has led to the successful unveiling of cancer characteristics that are critical to understanding how the disease works and progresses."

The study also defines a new therapeutic strategy for patients with prostate cancer, consisting of a combination of standard chemotherapy and two pharmacological agents that inhibit key signaling pathways associated with embryonic development and cell differentiation. Results showed that chemotherapy eliminated differentiated tumor cells, whereas the signaling pathway inhibitors selectively depleted the cancer stem cell population. Some of these inhibitors are already in clinical trials, and some are FDA-approved.

"By targeting these newly identified cancer 'stem' cells, we are attacking the foundation of tumor growth, rather than treating the symptoms of it," said Dr. Domingo-Domenech. "The novel discovery of this cell population could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies."

Ongoing studies suggest that this new cell type exist in other tumor types such as breast cancer, colon cancer, bladder cancer and lung cancer. Dr. Cordon-Cardo's team is studying these disease areas to determine the presence and impact of these cancer cells.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

Read more from the original source:
Chemotherapy-resistant cancer stem cell could be 'Achilles' heel' of cancer

Hero dog gets stem cell treatment

By Stem Cell Treatment

By Julie S. Alipala Inquirer Mindanao

ZAMBOANGA CITYKabang, the female Aspin dog who lost her upper snout when hit by a motorcycle while saving the lives of two girls, will be staying in Manila for two weeks for a stem cell treatment before further surgery in the United States.

Veterinarian Anton Lim said the stem cell treatment will boost the dogs immunity before she is flown to the US within the month. Kabang was flown to Manila on Sunday morning.

Lim said they were able to raise at least $10,000 from donations to shoulder expenses for Kabangs surgery on a protruding bone on her face. We are halfway there. As I have said, we need around $20,000, he said.

Team Kabang is really grateful for the global effort as we received donations from almost a dozen countries, he added. The Animal Welfare Coalition of the Philippines has also helped provide medicines for Kabang.

Follow Us

Recent Stories:

Tags: Animal Welfare Coalition of the Philippines , Aspin dog , Kabang , stem cell treatment , surgery

Factual errors? Contact the Philippine Daily Inquirer's day desk. Believe this article violates journalistic ethics? Contact the Inquirer's Reader's Advocate. Or write The Readers' Advocate:

Follow this link:
Hero dog gets stem cell treatment

Details revealed in complicated stem-cell case

By Stem Cell Treatment

September 08, 2012 10:01 PM

A Brownsville man admitted to charging a couple more than $8,000 to perform an unapproved stem-cell procedure on their child who had experienced neurological problems after nearly drowning.

Francisco Morales, 52, has pleaded guilty to a conspiracy to introduce misbranded and unapproved drugs into interstate commerce, U.S. Attorney Kenneth Magidson announced Friday.

Lawrence Stowe, 59, of Illinois, pleaded guilty to the same charges.

These pleas are a victory for the American public, in demonstrating the FDAs commitment to investigating cases of individuals and businesses that prey on the sick and vulnerable with phony medical treatments, said Patrick J. Holland of the Food and Drug Administrations Office of Criminal Investigations.

Alberto Ramon, 50, of Del Rio, and Vincent Dammai, 42, of Mount Pleasant, S.C., are also charged in the case and will go to trial in late November.

Magidson said in a press release that Morales and Stowe both falsely represented that they were licensed to practice medicine and that they each operated medical clinics in Brownsville.

In January 2006, Stowe admitted that he started using Stowe BioTherapy Inc. and The Stowe Foundation to advertise and promote a medical treatment protocol for several neurological diseases that have no cures.

The treatment was called Applied Biologics and consisted of supplements, vaccines, patient specific transfer factors and stem cell therapy. Stowe told patients that the FDA reviewed the treatment and considered it effective for Lou Gehrigs disease, MS and Parkinsons. There are no cures for these diseases.

Stowe and Morales pleaded guilty to introducing an unapproved drug called Immune Factor G-40, and Stowe further admitted that he introduced an unapproved treatment called patient specific transfer factors.

Read more from the original source:
Details revealed in complicated stem-cell case

→←